Ingen internetforbindelse — viser den gemte version af siden.

IQVIA Holdings In…

USUSD
← Til Screeneren

IQVIA Holdings Inc (LSE:0JDM) — Biotechnology: Commercial Physical & Biological Resarch. Antal børser, hvor selskabets aktier handles: 2. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
iqvia.com
Investorrelationer
ir.iqvia.com/
Sektor
Health Care · Biotechnology: Commercial Physical & Biological Resarch
Hovedkontor
Durham, United States
Administrerende Direktør
Ari Bousbib
Ansatte
94 000
Grundlagt
2016
Børsnoteret Siden
29.01.2018 (LSE:0JDM)
Udestående Aktier
164.6 mio. pr. 2026-07-21
Free Float
156.25 mio.
Markedsværdi
44.25 mia. USD
Insidere
1.09%
Institutionelle Investorer
103.42%
Branche (SIC)
Services-Commercial Physical & Biological Research
ISIN
US46266C1053
LEI
549300W3R20NM4KQPH86
P/E
47.1
Udbetalingsgrad
41.0%
FCF
2.12 mia. USD
Udbetaling / FCF
27%
Gæld
15.8 mia. USD
6.6 år FCF
Udbyttestreak
—
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 31.03.2026 (selskabets seneste rapport).
NAV
37.27 USD · P/NAV 7.00
Balancedato31.03.2026
Aktiver29.7 mia. USD
− Forpligtelser23.3 mia. USD
= Total Egenkapital6.35 mia. USD
− Ikke-Kontrollerende Interesser128 mio. USD
= NAV (aktiekapital i selskabets aktionærer)6.22 mia. USD
− Goodwill16.5 mia. USD
− Immaterielle Aktiver4.80 mia. USD
= Materiel NAV−15.1 mia. USD
Aktier166 900 000
NAV pr. Aktie37.27 USD
Håndgribelig NAV pr. Aktie−90.63 USD
Aktiekurs (0JDM)261.01 USD
P/NAV7.00
NAV-Historie
BalancedatoNAVNAV pr. Aktie
31.03.20266.22 mia. USD37.27 USD
31.12.20256.50 mia. USD38.34 USD
30.09.20256.16 mia. USD36.17 USD
30.06.20255.78 mia. USD33.99 USD
31.03.20255.98 mia. USD34.33 USD
31.12.20246.07 mia. USD34.45 USD
30.09.20246.97 mia. USD38.36 USD
30.06.20246.71 mia. USD36.83 USD
Beskrivelse

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

annonce

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksIQV primærUSD271.04 +3.45%almindelige aktier
LSE London Stock Exchange0JDM IOBUSD261.01 +0.00%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Ingen udbyttebetalinger fundet (tjekket 17.10.2026). Virksomheden udbetaler sandsynligvis ikke udbytte.

Nyheder Denne Uge

Pressemeddelelser fra virksomhedens investorhjemmeside, opdateret dagligt. Links fører til virksomhedens hjemmeside. Overskrifterne er på originalsproget, som på virksomhedens hjemmeside.

Største Ejere

EjerAndelAktierRapportdato
Blackrock Inc.8.84%14.55 mio.2026-06-30
Harris Associates L.P.7.4%12.18 mio.2026-06-30
Vanguard Capital Managem…6.63%10.91 mio.2026-06-30
State Street Corporation4.56%7.51 mio.2026-06-30
Vanguard Portfolio Manag…4.56%7.5 mio.2026-06-30
JPMORGAN CHASE & CO3.73%6.14 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…3.22%5.3 mio.2026-06-30
Artisan Partners Limited…2.88%4.74 mio.2026-06-30
Boston Partners2.71%4.47 mio.2026-06-30
Geode Capital Management…2.71%4.45 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.63%4.32 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.2%3.62 mio.2026-06-30
Invesco Ltd.1.99%3.28 mio.2026-06-30
HARRIS ASSOCIATES INVEST…1.58%2.61 mio.2026-06-30
HARRIS ASSOCIATES INVEST…1.56%2.57 mio.2026-06-30
iShares Trust-iShares Co…1.35%2.22 mio.2026-08-31
Fidelity Concord Street…1.31%2.16 mio.2026-07-31
SPDR S&P 500 ETF TRUST-S…1.24%2.04 mio.2026-08-31
VANGUARD WINDSOR FUNDS-V…1.07%1.76 mio.2026-07-31
VANGUARD INDEX FUNDS-Van…0.96%1.59 mio.2026-06-30
BOUSBIB ARI B (Chief Exe…≈0.84%1.38 mio.2026-07-29
BRUEHLMAN RONALD E (Chie…≈0.03%55 9962026-02-06
HAAS BERND (Officer)≈0.01%24 4142026-02-06
GRENFELL ALISTAIR (Offic…≈0.01%24 1242026-02-06
SHERBET ERIC M (General…≈0.01%20 9992026-07-29
LEONARD JOHN M (Director…≈0.01%16 9462026-04-23
GOGGINS COLLEEN A (Direc…≈0.01%14 4532026-04-23
STAUB WALTER. RICHARD II…≈0.01%13 3122026-08-03
FEDOCK MICHAEL J. (Offic…≈0.01%9 5952026-02-06
DANHAKL JOHN G (Director…——2026-04-23